Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal International Journal of Health Science and Technology
Budi Santoso
RSUP dr. Soeradji Tirtonegoro
Humanities Engineering Health Professions Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Diagnosis and therapy of adult type-2 inflammation chronic rhinosinusitis: a systematic literature review Budi Santoso; Dinar Rosmala
International Journal of Health Science and Technology Vol. 7 No. 3 (2026): April
Publisher : Universitas 'Aisyiyah Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31101/ijhst.v7i3.4508

Abstract

Adult type-2 inflammation chronic rhinosinusitis with nasal polyp impacts quality of life. Despite diagnosis and treatment advances, recurrence is common, prompting the exploration of new diagnosis and therapies. Objectives To review the current literature for the best diagnosis and therapy of adult type-2 inflammation chronic rhinosinusitis and future research to find new specific diagnoses and therapies. We conducted a literature review of PubMed, Google Scholar, Cochrane Library and others, August, 2 - 9, 2025. The search terms included “type-2 inflammation”, “chronic rhinosinusitis”, and “therapy”. We got 107 e-journals from: PubMed: 13, Google scholar: 11, Cochrane Library: 14, Others: 69. Type 2 inflammation is responsible for driving the disease in 80% to 90% of patients with nasal polyps (CRSwNP) and biomarkers for diagnosis include tissue/blood eosinophils, total IgE, and interleukin. Type 2 inflamation CRSwNP have high recurrence rates 38% to 60% at 12 months follow-up, and resistance to conventional medical or surgical treatment. Effectiveness of recent treatment for severe type 2 CRSwNP: corticosteroid effective for rapid reduction of inflammation, Endoscopic Sinus Surgery (ESS) is effective for restoring sinus drainage, and biological agents promosing future treatment. Future studies should investigate the optimal diagnostic techniques for individual patients based on underlying pathophysiology especially endotype and biomarker to better direct treatment and should assess the role of new therapies. The treatment of corticosteroid combine with antihistamine, new biologics agent and new surgery technic promising strategy for achieving therapeutic benefits type-2 inflammation chronic rhinosinusitis.
Biologics agent for chronic rhinosinusitis with nasal polyps: a systematic literature review Budi Santoso; Dinar Rosmala
International Journal of Health Science and Technology Vol. 8 No. 1 (2026): July
Publisher : Universitas 'Aisyiyah Yogyakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31101/ijhst.v8i1.4585

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) is commonly associated with type 2 inflammation, including increased eosinophils and elevated interleukins (IL)-4, IL-5, IL-9, IL-13, IL-25, and IL-33. Control of the disease may remain inadequate despite intranasal corticosteroids and endoscopic sinus surgery, creating a need for therapies directed at type 2 immune pathways. This systematic literature review summarizes the current knowledge base and major research directions concerning biologic treatment for CRSwNP. Literature was reviewed from PubMed, Google Scholar, Cochrane Library and other sources during May 10-15, 2026, using the terms “biologic” and “chronic rhinosinusitis with nasal polyps”; 127 e-journals were obtained. Across the reviewed literature, biologic therapy was associated with symptom improvement, a lower polyp burden, and less need for revision sinus surgery. Choice of treatment should be individualized according to defined clinical goals, while direct head-to-head trials are still needed to inform selection between agents. Long-term outcomes, combination strategies, and performance in routine clinical practice remain important research priorities. Biologic agents provide a developing therapeutic option for obtaining clinical benefit in CRSwNP.
Co-Authors Dinar Rosmala Dinar Rosmala